Navigation Links
Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
Date:8/13/2008

Patients to be Offered Additional Testing Services Provided by Interleukin

Genetics

WALTHAM, Mass., and BRENTWOOD, Tenn., Aug. 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), and OralDNA Labs, Inc., today announced the execution of a marketing, sales and distribution agreement for Interleukin Genetics' proprietary PST(R) Genetic Test. The PST(R) Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. Under the terms of the agreement, OralDNA will receive a non-exclusive license from Interleukin Genetics to market, sell and distribute Interleukin Genetics' proprietary PST(R) Genetic Test to dental practices within the United States. OralDNA will pay Interleukin Genetics a set fee per test for all tests sold by OralDNA and is responsible for all costs it incurs for marketing such tests. Patients will be asked in the informed consent if they would like to receive additional testing services, other than the PST(R) Genetic Test, provided by Interleukin Genetics.

Lewis H. Bender, Chief Executive Officer of Interleukin Genetics, commented, "We are pleased to have entered into this license agreement for OralDNA to market our PST(R) Genetic Test as a determinant of risk for periodontal disease. We believe that this relationship will allow our sales of this important product to grow with a sales force that specifically targets dental practices. In addition, we expect that this agreement with OralDNA Labs will enable our core strategy of growth through partnerships and should allow Interleukin Genetics to build a customer base to provide additional test services."

Brian C. Carr, Chief Executive Officer of OralDNA, commented, "We are very excited to be working with Interleukin Genetics and adding the PST(R) Genetic Test to our portfolio of diagnostic tests performed in our new U.S. based laboratory. We believe that by combining our MyPerioPath test, which identifies specific pathogenic bacteria causing an infection within the gum structure, with the PST(R) Genetic Test, we are providing the dental community with the proper tools to identify and treat periodontal disease. The combination of both tests creates a systematic way to track and maximize clinical outcomes for dental professionals and their patients. As we continue to understand the systemic link and risk factors associated with periodontal disease, it's important that we partner with companies who, like us, are focused on helping dental professionals identify and treat disease at its earliest onset."

About Periodontal Disease in the United States

Periodontal (gum) diseases, including gingivitis and periodontitis, are serious infections that, left untreated, can lead to tooth loss. Periodontal disease is a chronic bacterial infection that affects the gums and bone supporting the teeth. Periodontal disease is usually first diagnosed by the patients' dentist. About a third of adults will have at least 3 to 4 teeth affected with moderate periodontal disease. Severe or rapidly progressing disease affects 5 - 15 percent of the population. There are over 160,000 dentists in the U.S. who frequently perform diagnostic (86 percent) and preventive (79 percent) procedures. Over half of the population visits a dentist, usually twice a year. As a result, the average dental office sees approximately 4,000 patients each year and many of which will go on to develop periodontal disease. The U.S. dental market is valued at $70 - $96 billion annually with the average patient spending about $560 per year, over half of this on diagnostic and preventive procedures. Of the 128 million patients who visit a dentist each year, half are in the age range (18 to 54) most appropriate for PST risk assessment.

About PST(R) Genetic Test

PST(R) Genetic Test is a reliable way of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss. PST(R) Genetic Test is the first and only genetic test that analyzes interleukin 1 (IL1) genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for more severe periodontal disease. The PST(R) Genetic Test was developed following numerous clinical studies, and more than 40 peer-reviewed articles have been published on the test.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment.

Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com .

About OralDNA Labs

OralDNA Labs, Inc. is a specialty diagnostic company created to advance existing and future diagnostic capabilities as they are applied within oral medicine. The company's purpose is to supply the dental profession with reliable, definitive and cost effective clinical tests that help detect and diagnose disease at an earlier stage thus allowing for better clinical outcomes. For more information about OralDNA Labs, Inc., please visit http://www.OralDNA.com .

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
2. Interleukin Genetics to Present at 2008 BIO International Convention
3. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
4. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
5. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
7. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
9. Interleukin Genetics Retains Top Life Science Communications Firms
10. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
11. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)...  Allergan plc (NYSE: AGN ) a leading ... , Allergan,s CEO and President, will be featured as ... the RBC Capital Markets Healthcare Conference on Tuesday, February ... York Palace Hotel in New York, NY ... can be accessed on Allergan,s Investor Relations web site ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated network ... two long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical ... Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will assume ...
(Date:2/10/2016)... ... 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will feature ... in San Francisco’s Moscone Center from February 16-18, 2016, and at the healthcare-focused ... latest InGaAs PIN diode standard packages feature a TO-46 metal can with active areas ...
(Date:2/10/2016)... Mateo, CA (PRWEB) , ... February 10, 2016 ... ... of Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads ... September 2014. More than 1,600 participants have joined the PROMPT study, which seeks ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):